Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody

Molecular Imaging

Volumn 11, Issue 1, 2012, Pages 33-46

  Oliveira, Sabrina ^a,b,c   Van Dongen, Guus A M S ^a,b,c   Stigter Van Walsum, Marijke ^a,b,c   Roovers, Rob C ^a,b,c   Stam, Jord C ^a,b,c   Mali, Willem ^a,b,c   Van Diest, Paul J ^a,b,c   Van Bergen En Henegouwen, Paul M P ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-EGFR; CETUXIMAB; DIAGNOSTIC TOOLS; EPIDERMAL GROWTH FACTOR RECEPTORS; GROWTH FACTOR; HUMAN TUMORS; NEAR INFRARED; OPTICAL IMAGING; OPTICAL MOLECULAR IMAGING; OVER-EXPRESSION; POSTINJECTION; TUMOR SITE; TUMOR UPTAKE;

FLUOROPHORES; INFRARED DEVICES; MOLECULAR IMAGING; MONOCLONAL ANTIBODIES; OPTICAL IMAGE STORAGE; PROBES; VISUALIZATION;

TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL; ARTICLE; CELL STRAIN 3T3; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NUDE MOUSE;

ANIMALS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASMS; NIH 3T3 CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECTROSCOPY, NEAR-INFRARED;

EID: 84857266262     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00025     Document Type: Article

References (54)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74, doi:10.1056/NEJMra0707704. (Pubitemid 351398490)
2. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 Suppl 4:S3-8, doi:10.1016/S0959-8049(01)00230-1. (Pubitemid 32938123)
3. van der Groep P, Bouter A, van der Zanden R, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2004;96:712-3.
4. Mishani E, Abourbeh G, Eiblmaier M, et al. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008;14:2983-98, doi:10.2174/138161208786404326.
5. Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009;50:1199-202, doi:10.2967/jnumed.109.062117.
6. Liu Z, Liu Y, Jia B, et al. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010;9:2297-308, doi:10.1158/1535-7163.MCT-10-0444.
7. Milenic DE, Wong KJ, Baidoo KE, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008;23:619-31, doi:10.1089/cbr.2008.0493.
8. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-31, doi:10.2967/jnumed.108.054312.
9. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010;40:167-81, doi:10.1053/j.semnuclmed.2009.12.005.
10. Zhao H, Cui K, Muschenborn A, et al. Progress of engineered antibody-targeted molecular imaging for solid tumors. Mol Med Rep 2008;1:131-4.
11. Muyldermans S, Atarhouch T, Saldanha J, et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 1994;7: 1129-35, doi:10.1093/protein/7.9.1129. (Pubitemid 24282500)
12. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-8, doi:10.1038/363446a0. (Pubitemid 23179389)
13. Iqbal U, Trojahn U, Albaghdadi H, et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumors. Br J Pharmacol 2010;160:1016-28.
14. Cortez-Retamozo V, Lauwereys M, Hassanzadeh GG, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002;98:456-62, doi:10.1002/ijc.10212. (Pubitemid 34188691)
15. de Genst E, Saerens D, Muyldermans S, et al. Antibody repertoire development in camelids. Dev Comp Immunol 2006;30:187-98, doi:10.1016/j.dci. 2005.06.010. (Pubitemid 41405795)
16. Dolk E, van Vliet C, Perez JM, et al. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins 2005;59:555-64, doi:10.1002/prot.20378. (Pubitemid 40594299)
17. Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008;10:167-75, doi:10.1007/s11307-008-0133-8.
18. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008;49:788-95, doi:10.2967/jnumed.107.048538. (Pubitemid 351717545)
19. Tchouate-Gainkam LO, Keyaerts M, Caveliers V, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol 2010 Sep 24. [Epub ahead of print], doi:10.1007/s11307-010-0428-4.
20. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003;13:195-208. (Pubitemid 36790510)
21. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-80, doi:10.1101/gad.1047403. (Pubitemid 36307540)
22. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-8, doi:10.1038/nrc701. (Pubitemid 37328803)
23. Kaijzel EL, van der Pluijm G, Löwik CW. Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 2007;13:3490-7, doi:10.1158/1078-0432.CCR-07-0402. (Pubitemid 46955108)
24. Gioux S, Choi HS, Frangioni JV. Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging 2010;9:237-55.
25. Frenken LG, van der Linden RH, Hermans PW, et al. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 2000;78:11-21, doi:10.1016/S0168-1656(99) 00228-X. (Pubitemid 30084786)
26. Roovers, et al. A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
27. Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signalling and of tumor growth by antagonistic anti-EGFR Nanobodies. Cancer Immunol Immunother 2007;56:303-17, doi:10.1007/s00262-006-0180-4. (Pubitemid 46035901)
28. Honegger AM, Dull TJ, Felder S, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987;51:199-209, doi:10. 1016/0092-8674(87)90147-4.
29. Oliveira S, Schiffelers RM, van der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 2010;145:165-75, doi:10.1016/j.jconrel.2010.03.020.
30. van der Linden R, de Geus B, Stok W, et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods 2000;240:185-95, doi:10.1016/S0022-1759(00)00188-5. (Pubitemid 30347413)
31. Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010;80:731-8, doi:10.1016/j.bcp.2010.04.011.
32. Willmann JK, Bruggen NV, Dinkelborg LM, et al. Molecular imaging in drug development. Nat Rev Drug Discov 2008;7:591-607, doi:10.1038/nrd2290. (Pubitemid 351927724)
33. Pantaleo MA, Nannini M, Fanti S, et al. Molecular imaging of EGFR: it's time to go beyond receptor expression [letter]. J Nucl Med 2009;50:1195-6, doi:10.2967/jnumed.109.063909.
34. Tolmachev V. Molecular imaging of EGFR: it's time to go beyond receptor expression [letter]. J Nucl Med 2009;50:1196, doi:10.2967/jnumed.109.064188.
35. Kulbersh BD, Duncan RD, Magnuson JS, et al. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg 2007;133:511-5, doi:10.1001/ archotol.133.5.511. (Pubitemid 46799790)
36. Koyama Y, Barrett T, Hama Y, et al. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 2007;9:1021-9, doi:10. 1593/neo.07787. (Pubitemid 350255349)
37. Helman EE, Newman JR, Dean NR, et al. Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther 2010;10:166-71.
38. Ke S, Wen X, Gurfinkel M, et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 2003;63:7870-5. (Pubitemid 37466721)
39. Kovar JL, Volcheck WM, Chen J, et al. Purification method directly influences effectiveness of an epidermal growth factorcoupled targeting agent for noninvasive tumor detection in mice. Anal Biochem 2007;361:47-54, doi:10.1016/j.ab.2006.11.021. (Pubitemid 46027009)
40. Diagaradjane P, Orenstein-Cardona JM, Colón-Casasnovas NE, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res 2008;14:731-41, doi:10.1158/1078-0432.CCR-07-1958. (Pubitemid 351231154)
41. Kampmeier F, Niesen J, Koers A, et al. Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imaging 2010;37:1926-34, doi:10.1007/s00259-010-1482-5.
42. Weigum SE, Floriano PN, Christodoulides N, et al. Cell-based sensor for analysis of EGFR biomarker expression in oral cancer. Lab Chip 2007;7:995-1003, doi:10.1039/b703918b. (Pubitemid 47101743)
43. Vosjan MJ, Perk LR, Roovers RC, et al. Facile labelling of an antiepidermal growth factor receptor Nanobody with (68) Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging 2011;38:753-63.
44. Koppe MJ, Soede AC, Pels W, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer 2003;106:965-72, doi:10.1002/ijc.11304. (Pubitemid 37071679)
45. Fujimori K, Covell DG, Fletcher JE, et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8. (Pubitemid 20213280)
46. Tijink B, Laeremans T, Budde M, et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008;7:2288-97, doi:10.1158/1535-7163.MCT-07-2384.
47. Kossodo S, Pickarski M, Lin SA, et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 2010;12:488-99, doi:10.1007/s11307-009-0279-z.
48. van de Ven S, Wiethoff A, Nielsen T, et al. A novel fluorescent imaging agent for diffuse optical tomography of the breast: first clinical experience in patients. Mol Imaging Biol 2010;12:343-8, doi:10.1007/s11307-009-0269-1.
49. Shan L, Hao Y, Wang S, et al. Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging 2008;7:42-9.
50. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol 2010;65:500-16, doi:10.1016/j.crad.2010.03.011.
51. Oude-Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast 2009;18 Suppl 3:S66-73, doi:10.1016/S0960-9776(09)70276-0.
52. Gong H, Kovar J, Little G, et al. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 2010;12:139-49.
53. Miao Z, Ren G, Liu H, et al. Cy5.5-labeled Affibody molecule for near-infrared fluorescent optical imaging of epidermal growth factor receptor positive tumors. J Biomed Opt 2010;15:036007, doi:10.1117/1.3432738.
54. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71, doi:10.1158/1535-7163.MCT-09-0195.